🧬 Endocrinology Update: Gene Therapy in Diabetes, PCOS Biomarker, AI Glucose App and More
From gene therapy reversing diabetes in primates to Australia’s greenlight on a once-weekly growth hormone for kids—this week’s endocrinology update is packed with ground-breaking developments!
📌 In This Episode:
✔️ Gestational diabetes care redesign in the Netherlands cut referrals by 84.8 percent and insulin use by 46.8 percent, with a 9.7 percent drop in treatment costs
✔️ Global review identifies 34 clinical trials targeting pharmacological remission in type 2 diabetes, with most focusing on early-diagnosed patients
✔️ A1-Antitrypsin (A1AT) identified as a promising biomarker in PCOS, linked to androgen levels and circadian disruption
✔️ Preclinical gene therapy (GPX-002) shows potential to reprogram pancreatic alpha cells for insulin secretion in primates
✔️ FDA approves KHINDIVI, the first pediatric oral hydrocortisone solution for adrenal insufficiency—no refrigeration required
✔️ Australia approves SKYTROFA, a once-weekly growth hormone therapy for children aged 3–18 with growth hormone deficiency
✔️ IBM & Roche launch AI-powered Accu-Chek SmartGuide Predict app to forecast glucose levels and alert users of low readings 30 minutes in advance
✔️ Vietnam’s Davipharm launches EIMLER-10 for managing blood glucose with added cardio-renal protection in type 2 diabetes patients
✔️ NIH-funded diagnostic tool uses trans-epidermal water loss to predict diabetic foot ulcer recurrence, with a 35 percent recurrence in high-risk patients
📢 Stay Ahead in Endocrinology Research!
✅ Like, share, and subscribe for weekly updates on endocrinology, diabetes, PCOS, growth hormone, and more
#Endocrinology #DiabetesResearch #PCOS #GeneTherapy #GrowthHormone #AIinHealthcare #FDAApproval #ClinicalTrials #HealthTech #LucidQuest #LQVentures #MedicalInnovation #DigitalHealth #PediatricEndocrinology #ChronicDiseaseCare #BiotechNews